halometasone and Chronic-Disease

Chronic hand eczema is a common chronic inflammatory skin disease that influences public health. Staphylococcus aureus colonization plays important roles in chronic hand eczema morbidity and progression, which also correlated to chronicity and severity of the disease. In this multicenter clinical trial, we aim to investigate the relationship between S. aureus colonization and chronic hand eczema. Eighty patient volunteers diagnosed with chronic hand eczema in 4 hospitals from 4 cities participated in this study. Staphylococcus aureus colonization was determined using Polymerase Chain Reaction and fluorescent labeling probe to rapidly detect the endemic thermostable nuclease gene nuc of S. aureus in clinical samples. All patients were treated with Halometasone Triclosan Cream for 2 weeks. The changes of clinical symptom scores were observed during the follow-up time. We found that the severity of chronic hand eczema was related to S. aureus colonization. Chronic hand eczema would remain severer than others if S. aureus colonization was not eliminated. Eliminating S. aureus colonization could provide good effectiveness in treatment of chronic hand eczema. Therefore, we make a proposal that detection and treatment of S. aureus should be considered in the clinical treatment of chronic hand eczema.

Topics: Adult; Aged; Betamethasone; Chronic Disease; Dermatologic Agents; Drug Combinations; Eczema; Female; Hand; Humans; Male; Middle Aged; Prognosis; Severity of Illness Index; Skin Cream; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Triclosan

Four international, multicentre, comparative clinical trials were carried out by twenty-two dermatologists in 569 patients with non-infected chronic eczematous dermatoses in Austria, Germany, Spain, Switzerland and Yugoslavia. In these clinical trials halometasone ointment exhibited a very satisfactory therapeutic effect in all the five types of non-infected chronic eczematous dermatitis, namely chronic contact dermatitis, atopic dermatitis, lichen simplex chronicus, seborrhoeic dermatitis and nummular dermatitis. It yielded an overall success rate ('good' to 'very good' results) of 85% as against 71% obtained with the comparative preparations. With regard to therapeutic effect, halometasone ointment proved significantly superior (p = 0.0001) to Ultralan ointment but it was less effective than Dermovate ointment (p = 0.052). It yielded overall success rates higher than those obtained with Diproderm (84.6% versus 74.4%) and Synalar (88.5% versus 72%) ointments. Halometasone ointment was well tolerated and neither skin atrophy nor any systemic effect due to the transcutaneous systemic absorption of the corticoid was observed.

Topics: Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Chronic Disease; Clinical Trials as Topic; Eczema; Female; Humans; Male; Middle Aged; Ointments; Random Allocation

Fifty children suffering from non-infected chronic eczematous dermatoses were treated with an ointment containing 0.05% halometasone, a new high potency trihalogenated synthetic corticosteroid. Halometasone ointment does not contain parabens or perfumes. The trial population consisted of patients (under 1 to 16 years old) with non-infected chronic nummular dermatitis, seborrhoeic dermatitis, atopic dermatitis and contact dermatitis. Halometasone ointment yielded very satisfactory therapeutic results and exhibited an excellent tolerability. It produced 'good' or 'very good' results in 82% of the patients and gave an overall cure rate of 76%. The number of patients obtaining an early cure, i.e. in less than 30 days, was thirty-six (72%). An early onset of therapeutic effect, i.e. within 6 days of starting the treatment, was reported in 77.1% of the patients. All the children (including eighteen infants) tolerated halometasone ointment well and no adverse effects, either due to local skin intolerability or the transcutaneous systemic absorption of the corticoid, were observed in this trial, nor were any instances of skin atrophy reported. Cosmetic acceptability and ease of application were considered 'good' in forty-nine (98%) patients.

Topics: Administration, Topical; Adolescent; Anti-Inflammatory Agents; Betamethasone; Child; Child, Preschool; Chronic Disease; Clinical Trials as Topic; Eczema; Female; Humans; Infant; Male; Ointments

In an open non-comparative trial forty-three hospitalized patients with chronic psoriasis vulgaris were treated with 0.05% halometasone cream (without dressing) by day and 0.05% halometasone ointment (with occlusive dressing) at night. This combined regimen yielded good to very good results in 93.1% of the patients treated. The trial treatment was fairly well tolerated, did not have any systemic adverse effects and had to be discontinued in only one patient, due to severe pustular eruption at the site of application.

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Chronic Disease; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ointments; Psoriasis

This clinical evaluation to determine the long-term therapeutic efficacy and tolerability of 0.05% halometasone ointment was carried out in fifty patients (forty-one with psoriasis and nine with chronic eczema) by seven dermatologists in Austria and Switzerland. The ages ranged from 19 to 76 years and the total duration of illness was more than 5 years in 62% of the trial population. The duration of treatment varied from 38 to 103 days (38-60 days in twenty-two patients, 61-90 days in twenty-five patients and 91-103 days in three patients). All patients received two non-occlusive applications of halometasone ointment per day. In this long-term study halometasone ointment exhibited very satisfactory therapeutic efficacy and very good tolerability. 'Good' to 'very good' results were reported in 73% and 89% of the patients with psoriasis and chronic eczema treated with halometasone ointment, respectively. Adverse effects were reported in only two (4%) patients who had transient itching at the site of application. Neither skin atrophy nor any systemic effect due to the transcutaneous systemic absorption of the corticoid was observed in this study, nor were any instances of contact skin allergy reported.

Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Chronic Disease; Clinical Trials as Topic; Eczema; Female; Humans; Male; Middle Aged; Ointments; Psoriasis

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Chronic Disease; Dosage Forms; Female; Humans; Male; Middle Aged; Ointments; Psoriasis